FLKS - Flex Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6150
+0.0100 (+1.65%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.6050
Open0.6250
Bid0.0000 x 900
Ask0.0000 x 900
Day's Range0.5500 - 0.6300
52 Week Range0.2600 - 14.8154
Volume1,683,115
Avg. Volume1,602,666
Market Cap444,509
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 1, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • Benzinga

    The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...

  • Flex Pharma shareholders OK reverse-merger after drug failure
    American City Business Journals

    Flex Pharma shareholders OK reverse-merger after drug failure

    Flex Pharma was co-founded in 2014 by Nobel Prize Winner Rod MacKinnon and serial entrepreneur Christoph Westphal.

  • Business Wire

    Flex Pharma Announces Broker Authority to Vote on Certain Proposals

    Flex Pharma, Inc. (FLKS) today announced that on or about June 27, 2019 it will mail a supplement (the “Supplement”) to its proxy materials to provide stockholders with updated information regarding brokers’ discretionary authority to vote stockholders’ shares on Proposal 2 (regarding the reverse stock split) and Proposal 4 (regarding adjournment of the special meeting). In Flex Pharma’s proxy statement/prospectus/information statement dated April 29, 2019 relating to the special meeting of stockholders (the “Proxy Statement”), Flex Pharma stated that Proposals 1, 2, 3 and 4 in the Proxy Statement are considered non-discretionary matters under the rules of the New York Stock Exchange (“NYSE”) applicable to broker-dealers and, therefore, a stockholder’s broker will not be able to vote the stockholder’s shares of Flex Pharma’s common stock without specific instructions.

  • Benzinga

    Flex Pharma Falls After Salarius Pharma Merger Delay

    Flex Pharma (NASDAQ: FLKS ) shares are trading lower after the company announced more shareholder votes are required to complete its merger with Salarius Pharma despite “overwhelming support.” According ...

  • Business Wire

    Flex Pharma Announces Overwhelming Support to Date for the Proposed Merger with Salarius Pharmaceuticals but More Votes are Needed to Complete the Merger

    Flex Pharma, Inc. (FLKS) today announced that approximately 85% of shares voted to date support the proposed merger with Salarius Pharmaceuticals, LLC, an epigenetic oncology company. Flex Pharma adjourned the special meeting until July 12, 2019 in order to provide shareholders with more time to complete proxies and vote their shares. Flex Pharma’s CEO William McVicar stated, “We are very pleased that the vast majority of shareholders who voted support the merger with Salarius, consistent with the recommendations of both leading, independent proxy advisory services ISS and Glass-Lewis.” Flex Pharma’s Board of Directors also unanimously recommends voting “FOR” all proposals in the proxy statement/prospectus/information statement as the best way to preserve future shareholder value.

  • Business Wire

    Flex Pharma Announces that ISS and Glass Lewis Recommend Shareholders Vote “FOR” All Agenda Items relating to Flex’s Strategic Merger with Salarius Pharmaceuticals

    Flex Pharma, Inc. (FLKS) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis recommend that shareholders vote FOR all agenda items before or at Flex Pharma’s June 14 Special Shareholders Meeting. ISS and Glass Lewis are leading U.S. institutional voting advisory services. Salarius Pharmaceuticals, LLC, is a privately held clinical-stage oncology company targeting the epigenetic causes of cancers.

  • Associated Press

    Flex Pharma: 1Q Earnings Snapshot

    The Boston-based company said it had a loss of 12 cents per share. Losses, adjusted for stock option expense, were 11 cents per share. The biotech drug developer posted revenue of $105,000 in the period. ...

  • Business Wire

    Flex Pharma Reports First Quarter 2019 Financial Results

    Flex Pharma, Inc. , today announced its financial results for the three months ended March 31, 2019.

  • ACCESSWIRE

    FLKS ALERT: Monteverde & Associates PC Encourages Flex Pharma, Inc. Shareholders to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / April 26, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

  • PR Newswire

    Lifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc., Flex Pharma, Inc., MYnd Analytics, Inc., SunCoke Energy Partners, L.P., Top Image Systems Ltd., and Uniti Financial Corporation

    NEW YORK , April 5, 2019 /PRNewswire/ -- AmpliPhi Biosciences Corporation (APHB) Lifshitz & Miller  announces investigation into possible breach of fiduciary duties in connection with the sale of APHB ...

  • Business Wire

    Flex Pharma Reports Fourth Quarter and Fiscal 2018 Financial Results

    Flex Pharma, Inc. , today announced its financial results for the three months and fiscal year ended December 31, 2018.

  • Houston oncology co. aims to grow after merger announcement
    American City Business Journals

    Houston oncology co. aims to grow after merger announcement

    Salarius Pharmaceuticals announced plans to merge with Boston-based Flex Pharma Inc. (Nasdaq: FLKS).

  • PR Newswire

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flex Pharma, Inc. - FLKS

    NEW YORK , Feb. 26, 2019 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • Deal of the Week: Houston oncology co. to merge with struggling pharma co. in Boston
    American City Business Journals

    Deal of the Week: Houston oncology co. to merge with struggling pharma co. in Boston

    Houston-based Salarius Pharmaceuticals LLC, a clinical-stage oncology company, will merge with Boston-based Flex Pharma Inc. (Nasdaq: FLKS). The combined company will be named Salarius Pharmaceuticals Inc. and will focus on developing Salarius’ drugs. The deal is expected to close in the first half of 2019, with Flex Pharma stockholders and current Salarius investors owning approximately 19.9 percent and 80.1 percent of the combined company, respectively.

  • Houston oncology co. to merge with Boston’s struggling Flex Pharma
    American City Business Journals

    Houston oncology co. to merge with Boston’s struggling Flex Pharma

    The announcement comes about seven months after Flex Pharma announced it would lay off most of its employees and explore a potential sale or merger after ending a mid-stage trial of its lead drug.

  • FLKS News: Flex Pharma Stock Rockets Higher on Salarius Merger
    InvestorPlace

    FLKS News: Flex Pharma Stock Rockets Higher on Salarius Merger

    Flex Pharma stock was on the rise today following news of a merger with Salarius Pharmaceuticals. Source: amtec.us.com The deal will have a wholly owned subsidiary of Flex Pharma (NASDAQ:FLKS) merging with Salarius Pharmaceuticals. Once the deal is complete, FLKS will be changing its name to Salarius Pharmaceuticals. When the deal reaches completion, the current management team of Salarius Pharmaceuticals will lead the new company. Flex Pharma's President and CEO William McVicar will also join the company's Board of Directors. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The deal between the two companies will result in holders of Flex Pharma stock having a 19.9% stake in the new company. The remaining will belong to current investors of Salarius Pharmaceuticals. There is also a warrants option for holders of Flex Pharma stock that will allow them an additional 2.4% stake in the company. With the two companies merging to become one, the new focus will be on Salarius Pharmaceuticals pipeline of treatments for orphan cancers and other cancers without treatment options. Money from the combined company is expected to keep it running until mid-2020, which is enough time for it to report "early cohort data from an ongoing Phase 1 Ewing sarcoma trial." * 10 Oversold Stocks Due for a Bounce The deal between Flex Pharma and Salarius Pharmaceuticals already has the unanimous approval from both companies' Board of Directors. It still needs approval from investors in FLKS stock and Salarius Pharmaceuticals, as well as completing other customary closing conditions. If all goes well, the deal is set to close in the first half of 2019. FLKS stock was up 47% as of noon Friday. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Downtrodden Stocks to Fish From the Bottom * 8 Cheap Value Stocks That Just Got More Enticing * 5 Apple Suppliers Hurt by the Guidance Cut As of this writing, William White did not hold a position in any of the aforementioned securities. Compare Brokers The post FLKS News: Flex Pharma Stock Rockets Higher on Salarius Merger appeared first on InvestorPlace.

  • Benzinga

    Flex Pharma Finds A Lifeline In Merger With Oncology Biotech Salarius Pharma

    Embattled Flex Pharma Inc (NASDAQ: FLKS) announced a deal Friday to merge with privately held Salarius Pharma, an oncology company targeting the epigenetic causes of cancer. Following the closing of the deal, Flex shareholders would own about 19.9 percent of the combined company and Salarius shareholders the remaining 80.1 percent. Flex shareholders would also receive a right to receive warrants six months and a day after the closing of the deal, which gives them the option to purchase additional shares.

  • ACCESSWIRE

    4 Healthcare Stocks To Watch On Friday (1/4/19)

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. Premier Health Group (PHGRF) (PHGI), Flex Pharma, Inc. (NASDAQ: FLKS), Ampliphi Biosciences Corp (NYSE American: APHB), and Histogenics Corp (NASDAQ: HSGX) are 4 healthcare stocks worth checking out on Friday. Premier Health Group (PHGRF) (PHGI) enjoyed impressive gains as shares closed out Thursday's trading at $0.66 per share, up more than 7% from December 27's close of $0.62 per share.

  • Business Wire

    Flex Pharma and Salarius Pharmaceuticals Announce Merger Agreement to Accelerate Clinical Development of Novel Epigenetic Therapy for Cancer

    Flex Pharma, Inc. Management believes that the proposed transaction will position the combined company to recognize multiple value inflection points based on Salarius’ clinical pipeline, which targets rare, orphan cancers with no targeted treatments and cancers that have a high unmet need. Salarius recently completed a $6.4 million private placement, which combined with cash from Flex Pharma is expected to fund the combined company to mid-2020, allowing it to report early cohort data from an ongoing Phase 1 Ewing sarcoma trial.

  • Before You Buy Flex Pharma, Inc. (NASDAQ:FLKS), Consider Its Volatility
    Simply Wall St.

    Before You Buy Flex Pharma, Inc. (NASDAQ:FLKS), Consider Its Volatility

    If you're interested in Flex Pharma, Inc. (NASDAQ:FLKS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...

  • PR Newswire

    Asceneuron Appoints Dr. Thomas C. Wessel as Chief Medical Officer

    Asceneuron, an emerging leader in the development of innovative small molecules for the treatment of neurodegenerative diseases, announced today the appointment of Thomas C. Wessel, MD, PhD, as Chief Medical Officer. Tom has over 20 years of experience in the biopharmaceutical industry and will be responsible for progressing the development of Asceneuron's lead program ASN120290 and a pipeline of novel small molecules through the clinic. Tom will be based at Asceneuron's new offices in Cambridge, Massachusetts, where he will lead all regulatory and clinical development activities as part of the company's further expansion in the United States.

  • GlobeNewswire

    Analysis: Positioning to Benefit within Independence Holding, KVH Industries, Attunity, Flex Pharma, Westinghouse Air Brake Technologies, and Alaska Communications Systems Group — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.